Page 1247 - Clinical Immunology_ Principles and Practice ( PDFDrive )

CHaPTEr 89 Biological Modifiers of Inflammatory Diseases 1209

Features of Macrophage Activation Syndrome: Reanalysis of a Prior 49. Hueber W, Sands B, Lewitzky S, et al. Secukinumab, a human anti-IL-
Phase III Trial. Crit Care Med 2016;44(2):275–81. 17A monoclonal antibody, for moderate to severe Crohn’s disease:
32. Schlesinger N, Alten RE, Bardin T, et al. Canakinumab for acute gouty unexpected results of a randomised, double-blind placebo-controlled
arthritis in patients with limited treatment options: results from two trial. Gut 2012;61:1693–700.
randomised, multicentre, active-controlled, double-blind trials and their 50. Blauvelt A, Papp KA, Griffiths CEM, et al. Efficacy and Safety of
initial extensions. Ann Rheum Dis 2012;71:1839–48. Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis
33. Veldhoen M, Hocking RJ, Atkins CJ, et al. TGF-beta in the context of an from Two Phase III Randomized Clinical Trials in Moderate-to-Severe
inflammatory cytokine milieu supports de novo differentiation of Plaque Psoriasis (UNCOVER-2 and -3). Am J Clin Dermatol
IL-17-producing T cells. Immunity 2006;24(2):179–89. 2017;18(2):273–80.
34. Tilg H, Trehu E, Atkins MB, et al. Interleukin-6 (IL-6) as an 51. Lebwohl M, Strober B, Menter A, et al. Phase 3 Studies Comparing
anti-inflammatory cytokine: induction of circulating IL-1 receptor Brodalumab with Ustekinumab in Psoriasis. N Engl J Med
antagonist and soluble tumor necrosis factor receptor p55. Blood 2015;373(14):1318–28.
1994;83(1):113–18. 52. Mathian A, Hie M, Cohen-Aubart F, et al. Targeting interferons in
35. Grivennikov S, et al. IL-6 and STAT3 signaling is required for survival of systemic lupus erythematosus: current and future prospects. Drugs
intestinal epithelial cells and colitis associated cancer. Cancer Cell 2015;75(8):835–46.
2009;16(2):103–13. 53. Meka RR, Venkatesha SH, Dudics S, et al. IL-27-induced modulation of
36. Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor autoimmunity and its therapeutic potential. Autoimmun Rev
inhibition with tocilizumab reduces disease activity in rheumatoid 2015;14(12):1131–41.
arthritis with inadequate response to disease-modifying antirheumatic 54. Cai Z, Wong CK, Dong J, et al. Remission of systemic lupus
drugs. Arthritis Rheum 2008;58:2968–80. erythematosus disease activity with regulatory cytokine interleukin
37. Yokota S, Imagawa T, Mon M. Efficacy and safety of tocilizumab in (IL)-35 in Murphy Roths Large (MRL)/lpr mice. Clin Exp Immunol
patients with systemic-onset juvenile idiopathic arthritis: a randomized, 2015;181(2):253–66.
double-blind, placebo controlled, withdrawal phase III trial. Lancet 55. Cofiell R, Kukreja A, Bedard K, et al. Eculizumab reduces complement
2008;371:998–1006. activation, inflammation, endothelial damage, thrombosis, and renal
38. Ortiz-Sanjuán F, Blanco R, Calvo-Rio V, et al. Efficacy of tocilizumab in injury markers in aHUS. Blood 2015;125(21):3253–62.
conventional treatment-refractory adult-onset Still’s disease: multicenter 56. Zikos TA, Sokolove J, Ahuja N, et al. Eculizumab Induces Sustained
retrospective open-label study of thirty-four patients. Arthritis Remission in a Patient With Refractory Primary Catastrophic
Rheumatol 2014;66(6):1659–65. Antiphospholipid Syndrome. J Clin Rheumatol 2015;21(6):
39. Kawabata H, Kotani S, Matsumura Y, et al. Successful treatment of a 311–13.
patient with multicentric Castleman’s disease who presented with 57. El-Husseini A, Hannan S, Awad A, et al. Thrombotic microangiopathy in
thrombocytopenia, ascites, renal failure and myelofibrosis using systemic lupus erythematosus: efficacy of eculizumab. Am J Kidney Dis
tocilizumab, an anti-interleukin-6 receptor antibody. Intern Med 2015;65(1):127–30.
2013;52(13):1503–7. 58. Miller DH, Khan OA, Sheremata WA, et al. International Natalizumab
40. Barkhausen T, Tschernig T, Rosenstiel P, et al. Selective blockade of Multiple Sclerosis Trial Group. A controlled trial of natalizumab for
interleukin-6 trans-signaling improves survival in a murine relapsing multiple sclerosis. N Engl J Med 2003;348(1):15.
polymicrobial sepsis model. Crit Care Med 2011;39(6):1407–13. 59. Ghosh S, Goldin E, Gordon F, et al. Natalizumab for active Crohn’s
41. Sodenkamp J, Waetzig GH, Scheller J, et al. Therapeutic targeting of disease. N Engl J Med 2003;348(1):24–32.
interleukin-6 trans-signaling does not affect the outcome of 60. Glatigny S, Duhen R, Oukka M, et al. Cutting edge: loss of α4 integrin
experimental tuberculosis. Immunobiology 2012;217(10): expression differentially affects the homing of Th1 and Th17 cells. J
996–1004. Immunol 2011;187(12):6176–9.
42. Murphy CA, Langrish CL, Chen Y, et al. Divergent pro- and 61. Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab
antiinflammatory roles for IL-23 and IL-12 in joint autoimmune induction therapy for patients with Crohn’s disease in whom tumor
inflammation. J Exp Med 2003;198(12):1951–7. necrosis factor antagonist treatment failed. Gastroenterology
43. Ritchlin C, Rahman P, Kavanaugh A, et al; PSUMMIT 2 Study Group. 2014;147(3):618–27.
Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, 62. Manzi S, Sánchez-Guerrero J, Merrill JT, et al; BLISS-52 and BLISS-76
ustekinumab, in patients with active psoriatic arthritis despite Study Groups. Effects of belimumab, a B lymphocyte stimulator-specific
conventional non-biological and biological anti-tumour necrosis factor inhibitor, on disease activity across multiple organ domains in patients
therapy: 6-month and 1-year results of the phase 3, multicentre, with systemic lupus erythematosus: combined results from two phase III
double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann trials. Ann Rheum Dis 2012;71(11):1833–8.
Rheum Dis 2014;73(6):990–9. 63. Stohl W, Hiepe F, Latinis KM, et al. Belimumab reduces autoantibodies,
44. Wils P, Bouhnik Y, Michetti P, et al; Groupe d’Etude Thérapeutique des normalizes low complement, and reduces select B-cell populations in
Affections Inflammatoires du Tube Digestif (GETAID). Subcutaneous patients with systemic lupus erythematosus. Arthritis Rheum
Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With 2012;64(7):2328–37.
Crohn’s Disease Refractory to Anti-Tumor Necrosis Factor Agents. Clin 64. Chatham WW, Wallace DJ, Stohl W, et al; on behalf of the BLISS-76
Gastroenterol Hepatol 2016;14(2):242–50. Study Group. Effect of Belimumab on Vaccine Antigen Antibodies to
45. Isailovica N, Daigob K, Mantovanib A, et al. Interleukin-17 and innate Influenza, Pneumococcal, and Tetanus Vaccines in Patients with
immunity in infections and chronic inflammation. J Autoimmunity Systemic Lupus Erythematosus in the BLISS-76 Trial. J Rheumatol
2015;60:1–11. 2012;39(8):1632–40.
46. Menon B, Gullick NJ, Walter GJ, et al. Interleukin-17+CD8+ T cells are 65. Chatham WW, Chadha A, Fettiplace J, et al. Arthritis Rheumatol
enriched in the joints of patients with psoriatic arthritis and correlate 2016;68:748.
with disease activity and joint damage progression. Arthritis Rheumatol 66. Coquery CM, Loo WM, Wade NS, et al. BAFF regulates follicular helper
2014;66(5):1272–81. T cells and affects their accumulation and interferon-γ production in
47. Mease PJ, McInnes IB, Kirkham B, et al; FUTURE 1 Study Group. autoimmunity. Arthritis Rheumatol 2015;67(3):773–84.
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic 67. He B, Santamaria R, Xu W, et al. The transmembrane activator TACI
Arthritis. N Engl J Med 2015;373(14):1329–39. triggers immunoglobulin class switching by activating B cells through
48. Baeten D, Sieper J, Braun J, et al; MEASURE 1 Study Group; MEASURE the adaptor MyD88. Nat Immunol 2010;11(9):836–45.
2 Study Group. Secukinumab, an Interleukin-17A Inhibitor, in 68. Stohl W, Merrill JT, Looney RJ, et al. Treatment of systemic lupus
Ankylosing Spondylitis. N Engl J Med 2015;373(26):2534–48. erythematosus patients with the BAFF antagonist “peptibody”